BioInvent International AB (BOVNF)
4.70
0.00 (0.00%)
USD |
OTCM |
Nov 13, 16:00
BioInvent International Revenue (Quarterly): 1.23M for Sept. 30, 2024
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 1.23M |
| June 30, 2024 | 0.4323M |
| March 31, 2024 | 0.5729M |
| December 31, 2023 | 1.443M |
| September 30, 2023 | 2.484M |
| June 30, 2023 | 1.246M |
| March 31, 2023 | 1.559M |
| December 31, 2022 | 1.932M |
| September 30, 2022 | 1.709M |
| June 30, 2022 | 27.69M |
| March 31, 2022 | 1.788M |
| December 31, 2021 | 0.5551M |
| September 30, 2021 | 0.3465M |
| June 30, 2021 | 0.6291M |
| March 31, 2021 | 0.7405M |
| December 31, 2020 | 11.48M |
| September 30, 2020 | 1.838M |
| June 30, 2020 | 1.619M |
| March 31, 2020 | 1.738M |
| December 31, 2019 | 2.644M |
| September 30, 2019 | 1.884M |
| June 30, 2019 | 3.483M |
| March 31, 2019 | 1.899M |
| December 31, 2018 | 1.147M |
| September 30, 2018 | 0.7878M |
| Date | Value |
|---|---|
| June 30, 2018 | 1.131M |
| March 31, 2018 | 1.398M |
| December 31, 2017 | 1.627M |
| September 30, 2017 | 0.8787M |
| June 30, 2017 | 1.291M |
| March 31, 2017 | 1.454M |
| December 31, 2016 | 3.406M |
| September 30, 2016 | 0.0953M |
| June 30, 2016 | 1.255M |
| March 31, 2016 | 3.478M |
| December 31, 2015 | 1.174M |
| September 30, 2015 | 0.1965M |
| June 30, 2015 | 0.4344M |
| March 31, 2015 | 0.074M |
| December 31, 2014 | 0.225M |
| September 30, 2014 | 1.592M |
| June 30, 2014 | 4.918M |
| March 31, 2014 | 0.2731M |
| December 31, 2013 | 7.678M |
| September 30, 2013 | 1.195M |
| June 30, 2013 | 1.873M |
| March 31, 2013 | 1.809M |
| December 31, 2012 | 1.399M |
| September 30, 2012 | 1.911M |
| June 30, 2012 | 0.9005M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
0.3465M
Minimum
Sep 2021
27.69M
Maximum
Jun 2022
3.184M
Average
1.589M
Median
Revenue (Quarterly) Benchmarks
| Abliva AB | -- |
| Oncopeptides AB | 0.26M |
| Hansa Biopharma AB | 4.689M |
| BioArctic AB | 4.673M |
| Camurus AB | 46.21M |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | -9.370M |
| Total Expenses (Quarterly) | 11.55M |
| EPS Diluted (Quarterly) | -0.1426 |
| Enterprise Value | 215.05M |
| Profit Margin (Quarterly) | -761.8% |
| Earnings Yield | -12.57% |
| Normalized Earnings Yield | -13.37 |